Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 3, 2006, Pages 953-963

  Oh, Dong Jin ^a,b   Martin, Jonathan L ^a   Williams, Adrienne J ^a   Peck, Rachel E ^a   Pokorny, Corinna ^a   Russell, Paul ^c   Birk, David E ^d   Rhee, Douglas J ^a,b,d  

^a WILLS EYE HOSPITAL   (United States)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; INTERSTITIAL COLLAGENASE; LATANOPROST; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 24; MESSENGER RNA; STROMELYSIN; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; PROSTAGLANDIN F; RNA;

ARTICLE; CELL CULTURE; CILIARY BODY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADULT; AGED; CULTURE TECHNIQUE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; SMOOTH MUSCLE; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CELL CULTURE TECHNIQUES; CILIARY BODY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MATRIX METALLOPROTEINASES; MIDDLE AGED; MUSCLE, SMOOTH; ORGAN CULTURE TECHNIQUES; PROSTAGLANDINS F, SYNTHETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASES; UP-REGULATION;

EID: 33645387526     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0516     Document Type: Article

References (80)

1. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 1991;325:1412-1417.
2. Tielsche JM, Sommer A, Witt K, Katz J, Royall RM. Blindness and visual impairment in an American urban population: the Baltimore Eye Survey. Arch Ophthalmol. 1990;108:286-290.
3. Martin MJU, Sommer A, Gold EB, Diamond EL. Race and primary open-angle glaucoma. Am J Ophthalmol. 1985;99:383-387.
4. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
5. Bergea B, Bodin L, Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology. 1999;106:997-1005.
6. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487-497.
7. Mao LK, Steward WC, Shield MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol. 1991;111:51-55.
8. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, and Hussein M, for the Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression. Arch Ophthalmol. 2002;120:1268-1279.
9. Kass MA, Gordon MO, Hoff MR, et al. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. Arch Ophthalmol. 1989;107:1590-1598.
10. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side-effects of 0.005% latanoprost applied once daily, evening or morning: A comparison with timolol. Ophthalmology. 1995;102:1743-1752.
11. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147.
12. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost and timolol in primary open-angle glaucoma and ocular hypertension: a 12 week study. Arch Ophthalmol. 1996;114:929-932.
13. 2α-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989;48:707-716.
14. Stjernschantz J, Selen G, Ocklind A, Resul B. Effects of latanoprost and related prostaglandin analogues. In: Alm A, Weinreb RN, eds. Uveoscleral Outflow. Biology and Clinical Aspects. London: Mosby-Wolfe Medical Communications; 1998:57-72.
15. 2a analogue. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:513-518.
16. Lee P, Podos SM, Severin C. Effect of prostaglandin F2a on aqueous humor dynamics of rabbit, cat, and monkey. Invest Ophthalmol Vis Sci. 1984;25:1087-1093.
17. 2α or epinephrine on cynomolgus monkey eyes. I. Aqueous humor dynamics. Invest Ophthalmol Vis Sci. 1987;28:463-469.
18. 2α. Exp Eye Res. 1988;47:761-769.
19. 2a-1-isopropylester on anterior segment morphology. In: Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York: Allan R. Liss Inc.; 1989:737-776.
20. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.
21. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 2000;19:623-629.
22. Weinreb RN, Kashiwagi K, Kashiwagi F, Tuskahara S, Lindsey JD. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997;38:2772-2780.
23. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179-191.
24. El-Shabrawi Y, Eckhardt M, Berghold A, et al. Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone. Eye. 2000;14:375-383.
25. Lindsey JD, Kashiwagi K, Boyle D, Kashiwagi F, Firestein GS, Weinreb RN. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 1996;15:869-875.
26. Anthony TL, Lindsey JD, Weinreb RN. Latanoprost's effects on TIMP-1 and TIMP-2 expression in human ciliary muscle cells. Invest Ophthalmol Vis Sci. 2002;43:3705-3711.
27. Baker AH, Edwards, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002;115:3719-3727.
28. Lambert E, Dassa E, Haye B, Petitfrere E. TIMPs as multifunctional proteins. Crit Rev Oncol Hematol. 2004;49:187-198.
29. Khasigov PZ, Podobed OV, Gracheva TS, Salbiev KD, Grachev SV, Berezov TT. Role of matrix metalloproteinases and their inhibitors in tumor invasion and metastasis. Biochemistry (Mosc). 2003;68:711-717.
30. Curran S, Dundas SR Buxton J, Leeman MF, Ramsay R, Murray GI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res. 2004;10:8229-8234.
31. Zhou X, Hovell CJ, Pawley S, et al. Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrinolysis. Liver Int. 2004;24:492-501.
32. Maata M, Tervahartiala T, Harju M, Airaksinen J, Autio-Harmainen H, Sorsa T. Matrix metalloproteinases and their tissue inhibitors in aqueous humor of patients with primary open-angle glaucoma, exfoliation syndrome, and exfoliation glaucoma. J Glaucoma. 2005;14:64-69.
33. Steinmetz EF, Buckley C, Shames ML, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg. 2005;241:92-101.
34. Ahmed Z, Dent RG, Leadbeater WE, Smith C, Berry M, Logan A. Matrix metalloproteinases: degradation of the inhibitory environment of the transected optic nerve and the scar by regenerating axons. Mol Cell Neurosci. 2005;28:64-78.
35. Pauschinger M, Chandrasekharan K, Schultheiss JP. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system. Heart Fail Rev. 2004;9:21-31.
36. Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A: a kinetic study. J Biol Chem. 1998;273:871-880.
37. Butler GS, Will H, Atkinson SJ, Murphy G. Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. Eur J Biochem. 1997;244:653-657.
38. Rhee DJ, Tamm ER, Russell P. Donor corneoscleral buttons: a new source of trabecular meshwork for research. Exp Eye Res. 2003;2003:749-756.
39. 2α on calcium efflux. Invest Ophthalmol Vis Sci. 1992;33:2679-2686.
40. Dutkiewicz R, Albert DM, Levin LA. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res. 2000;70:563-569.
41. Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47(suppl 1):S6-S12.
42. Giambernardi AM, Grant GM, Taylor GP, et al. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol. 1998;16:483-496.
43. Martin J, Eynstone L, Davies M, Steadman R. Induction of metalloproteinases by glomerular mesangial cells stimulated by proteins of the extracellular matrix. J Am Soc Nephrol. 2001;12:88-96.
44. Grant GM, Giambernardi AM, Grant AM, Klebe RJ. Overview of expression of matrix metalloproteinases (MMP-17, MMP-18, and MMP-20) in cultured human cells. Matrix Biology. 1999;18:145-148.
45. Konttinen YT, Ainola M, Valleala H, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheumatol Dis. 1999;58:691-697.
46. Fortunato SJ, Menon R. Screening of novel matrix matalloproteinases (MMPs) in human fetal membranes. J Assist Reprod Genet. 2002;19:483-486.
47. Saghizadeh M, Brown DJ, Castellon R, et al. Overexpression of matrix metalloproteinase-10 and matrix metalloproteinase-3 in human diabetic corneas: a possible mechanism of basement membrane and integrin alterations. Am J Pathol. 2001;158:723-734.
48. Fortunato SJ, Menon R, Lombardi SJ. Presence of four tissue inhibitors of matrix metalloproteinases (TIMP-1, -2, -3, and -4) in human fetal membranes. Am J Reprod Immunol. 1998;40:395-400.
49. Weinreb RN, Lindsey JD. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci. 2002;43:716-722.
50. Gaton DD, Sagara T, Lindsey JD, Weinreb RN. Matrix metalloproteinase-1 localization in the normal human uveoscleral outflow pathway. Invest Ophthalmol Vis Sci. 1999;40:363-369.
51. Lan J, Kumar RK, Di Girolamo N, McCluskey P, Wakefield D. Expression and distribution of matrix metalloproteinases and their inhibitors in the human iris and ciliary body. Br J Ophthalmol. 2003;87:208-211.
52. Hernandez-Barrantes S, Bernardo M, Toth M, Friedman R. Regulation of membrane type-matrix metalloproteinases. Semin Cancer Biol. 2002;12:131-138.
53. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. J Biol Chem. 1995;1995270:5331-5338.
54. Deryugina EI, Bourdon MA, Jungwirth K, Smith JW, Strongin AY. Functional activation of integrin αVβ3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int J Cancer. 2000;86:15-23.
55. Nagase H. Cell surface activation of progelatinase A (proMMP-2) and cell migration. Cell Res. 1998;8:179-186.
56. Knauper V, Will H, Lopez-Otin C, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation: evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J Biol Chem. 271:17124-17131.
57. Parshley DE, Bradley JMB, Samples JR, Van Buskirk EM, Acott TS. Early changes in matrix metalloproteinases and inhibitors after in vitro laser treatment to the trabecular meshwork. Curr Eye Res. 1995;14:537-544.
58. Pang HH, Fleenor DL, Hellberg PE, Stropki K, McCartney MD, Clark AF. Aqueous outflow-enhancing effect of tert-butylhydroquinone: involvement of AP-1 activation and MMP-3 expression. Invest Ophthalmol Vis Sci. 2003;44:3502-3510.
59. Ishiguro N, Kojima T. Role of aggrecanase and MMP in cartilage degradation. Clin Calcium. 2004;14:38-44.
60. Arai M, Anderson D, Kurdi Y, et al. Effect of adenovirus-mediated over expression of bovine ADAMTS-4 and human ADAMTS-5 in primary bovine articular chondrocyte pellet culture system. Osteoarthritis Cartilage. 2004;12:599-613.
61. Flannery CR, Zeng W, Corcoran C, et al. Autocataltic cleavage of ADAMTS-4 (aggrecanase-1) reveals multiple glycosaminoglycanbinding sites. J Biol Chem. 2002;277:42775-42780.
62. English WR, Puente XS, Freije JM, et al. Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2. J Biol Chem. 2000;275:14046-14055.
63. Wang Y, Johnson AR, Ye QZ, Dyer RD. Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain. J Biol Chem. 1999;274:33043-33049.
64. Gauthier MC, Racine C, Ferland C, et al. Expression of membrane type-4 matrix metalloproteinase (metalloproteinase-17) by human eosinophils. Int J Biochem Cell Biol. 2003;35:1667-1673.
65. Yu WH, Yu S, Meng Q, Brew K, Woessner JF Jr. TIMP-3 binds to sulphated glycosaminoglycans of the extracellular matrix. J Biol Chem. 2000;275:31226-31232.
66. Pavloff N, Staskus PW, Kishnani NS, Hawkes SP. A new inhibitor of metalloproteinases from chicken: ChIMP-3-a third member of the TIMP family. J Biol Chem. 1992;267:17321-17326.
67. Yang TT, Hawkes SP. Role of the 21-kDa protein TIMP-3 in oncogenic transformation of culture chicken embryo fibroblasts. Proc Natl Acad Sci USA. 1992;89:10676-10680.
68. Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5) J Biol Chem. 2001;276:12501-12504.
69. Nagase H, Brew K. Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochem Soc Symp. 2003;70:201-212.
70. Amour A, Slocombe PM, Webster A, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 1998;435:39-44.
71. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. Tissue inhibitor of metalloproteinase-3 (TIMP-3) is an extracellular matrixassociated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem. 1994;269:9352-9360.
72. Apte SS, Hayashi K, Seldin MF, Mattei MG, Hayashi M, Olsen BR. Gene encoding a novel murine tissue inhibitor of metalloproteinases TIMP), TIMP-3, is expressed in developing mouse epithelia, cartilage, and muscle, and is located on mouse chromosome 10. Dev Dyn. 1994;200:177-197.
73. Slawomir M, Wojtowicz-Praga, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Investig New Drugs. 1997;15:61-75.
74. Will H, Atkinson SJ, Butler GS, Smith B, Murphy G. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J Biol Chem. 1996;271:17119-17123.
75. Tabata Y, Isashicki Y, Kamimura K, Nakao K, Ohba N. A novel splice site mutation in the tissue inhibitor of the metalloproteinases-3 gene in Sorsby's fundus dystrophy with unusual clinical feathers. Hum Genet. 1998;103:179-182.
76. Bond M, Murphy G, Bennett, MR, Newby AC, Baker AH. Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem. 2002;277:13787-13795.
77. Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. Inhibition of invasion and induction of apoptotic cell death in cancer cell lines by over expression of TIMP-3. Br J Cancer. 1999;79:1347-1355.
78. Ahonen M, Baker AH, Kahari VM. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinase-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res. 1998;58:2310-2315.
79. Weinreb RN, Lindsey JD, Marchenko G, Marchenko N, Angert M, Strongin A. Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest Ophthalmol Vis Sci. 2004;45:4368-4377.
80. Camras CB, Hedman K, US Latanoprost Study Group. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma. 2003;12:466-469.